Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Northwest Biotherapeutics (NWBO) over the last 16 years, with Q3 2025 value amounting to $202000.0.

  • Northwest Biotherapeutics' Capital Expenditures rose 1477.27% to $202000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $677000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $1.0 million for FY2024, which is 7049.75% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Capital Expenditures stood at $202000.0, which was up 1477.27% from $304000.0 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Capital Expenditures ranged from a high of $2.7 million in Q3 2021 and a low of $58000.0 during Q1 2022
  • For the 5-year period, Northwest Biotherapeutics' Capital Expenditures averaged around $735105.3, with its median value being $408000.0 (2022).
  • In the last 5 years, Northwest Biotherapeutics' Capital Expenditures tumbled by 8974.36% in 2022 and then soared by 219827.59% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Capital Expenditures (Quarter) stood at $1.6 million in 2021, then surged by 39.09% to $2.2 million in 2022, then crashed by 80.65% to $418000.0 in 2023, then plummeted by 81.34% to $78000.0 in 2024, then skyrocketed by 158.97% to $202000.0 in 2025.
  • Its last three reported values are $202000.0 in Q3 2025, $304000.0 for Q2 2025, and $93000.0 during Q1 2025.